MedPath

Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Phase 4
Completed
Conditions
Cardiovascular Diseases
Interventions
Registration Number
NCT00738296
Lead Sponsor
Hospital Universitario 12 de Octubre
Brief Summary

Comparison of the effect on the progression of the carotid intima-media interphase thickness (GIM), arterial rigidity according to the measurement of the pulse wave speed and direct measurement of the carotid and aortic rigidities and an inflammation marker (PCR) in patients with established cardiovascular disease (myocardial infarct, atherosclerotic coronary disease), diabetes mellitus type 2 or equivalent risk of coronary disease and a low density lipoprotein level \> 100 mg/dL, treated with simvastatin, pravastatin or the combination of simvastatin-ezetimibe during a period of at least one year.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Ldl-C Levels >100 Mg/Dl
  • Patients Who Have Signed The Consent
  • Patients Of ages between 30 and 75 Years Old
  • Patients Of Both Genders
  • Patients With Established Cardiovascular Disease, Diabetes With Or Without Established Cardiovascular Disease
  • Patients Without Previous Treatment With Ezetimibe
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cezetimibe (+) simvastatinGroup C: Drug
BpravastatinGroup B: Comparator
AsimvastatinGroup A: Comparator
Primary Outcome Measures
NameTimeMethod
The annual progression of the slope of the maximum average GIM and the arterial rigidity.1 Year
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath